Drug Trial Radar · NCT07262333
A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Dec 25, 2025
Primary completion
Dec 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Beijing Continent Pharmaceutical Co, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- First posted
- Dec 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Hydronidone capsules are pyridinone-based small molecule compounds. Hydronidone has not been approved for commercial sale both domestically and internationally. The applicant has completed the preliminary Phase I and Phase II clinical trials. The results showed that Hydronidone is a safe and effective drug for treating liver fibrosis in chronic hepatitis B, and it has good safety and tolerability. Based on the preliminary clinical research, a special population study has been initiated. The aim is to investigate the pharmacokinetic differences and safety of honginone capsules in patients with renal insufficiency and healthy subjects, in order to provide a basis for the clinical medication of patients with renal dysfunction.
Conditions
- Renal Insufficiency Chronic
Interventions
Hydronidone capsulesDrug
Take 90mg orally on an empty stomach on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The plasma drug concentrations of hydronidone and its metabolites M3 and M4(AUC0-∞)Time frame: 48 hours after administration
- The free plasma concentration of hydronidoneTime frame: 48 hours after administration
- The urine drug concentrations of hydronidone and its metabolites M3 and M4Time frame: 48 hours after administration
- The plasma drug concentrations of hydronidone and its metabolites M3 and M4(AUC%Extrap)Time frame: 48 hours after administration
- The plasma drug concentrations of hydronidone and its metabolites M3 and M4( AUC0-t)Time frame: 48 hours after administration
- The plasma drug concentrations of hydronidone and its metabolites M3 and M4(CL/F)Time frame: 48 hours after administration
- The plasma drug concentrations of hydronidone and its metabolites M3 and M4(Vd/F)Time frame: 48 hours after administration
- The plasma drug concentrations of hydronidone and its metabolites M3 and M4(Cmax)Time frame: 48 hours after administration
- The plasma drug concentrations of hydronidone and its metabolites M3 and M4(T1/2)Time frame: 48 hours after administration
- The plasma drug concentrations of hydronidone and its metabolites M3 and M4(λz)Time frame: 48 hours after administration
- The plasma drug concentrations of hydronidone and its metabolites M3 and M4(Tmax)Time frame: 48 hours after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Hubei, Wuhan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.